In a patient with acute subdural hemorrhage, should statin therapy be paused or continued?

Statin Management in Acute Subdural Hemorrhage

In patients with acute subdural hemorrhage, statins should generally be continued rather than discontinued, as abrupt cessation is associated with significantly worse outcomes including increased mortality. 1

Primary Recommendation

Continue statin therapy during acute subdural hemorrhage hospitalization unless there is a specific contraindication. The evidence strongly suggests that:

• Continuing statins is associated with 4.25-fold higher odds of 30-day survival compared to discontinuation 1
• Discontinuing statins increases mortality risk by 6.9-fold within 30 days compared to continued therapy 2
• Patients who continue statins have 2.57-fold higher odds of discharge to home or acute rehabilitation 1

Evidence-Based Rationale

The 2022 AHA/ASA guidelines acknowledge uncertainty regarding statin use in intracerebral hemorrhage (ICH), stating the "risks and benefits of statin therapy on ICH outcomes and recurrence relative to overall prevention of cardiovascular events are uncertain" 3. However, this guideline uncertainty reflects the lack of randomized trials, not evidence of harm.

The strongest observational evidence favors continuation:

• A large retrospective cohort of 3,481 ICH patients demonstrated that statin users had dramatically better survival and functional outcomes 1
• Instrumental variable modeling (controlling for unmeasured confounders) confirmed these benefits were real, not just selection bias 1
• A matched-cohort study of 323 patients found statin discontinuation carried 3.87-fold higher risk of 30-day death compared to matched controls 2

Clinical Decision Algorithm

For patients on statins prior to subdural hemorrhage:

1. Continue current statin therapy at the same dose during hospitalization
2. Do NOT discontinue based solely on the presence of intracranial hemorrhage
3. Monitor for hematoma expansion with standard neuroimaging protocols (not statin-specific)

Special considerations:

• Lobar hemorrhage location: The 2015 ICH guidelines suggest "avoidance of statins should be considered in patients with ICH, particularly those with lobar ICH" 4, but this recommendation predates the strong observational data showing harm from discontinuation
• Balance cardiovascular risk: Patients with established atherosclerotic disease, prior MI, or coronary stents face substantial thrombotic risk if statins are stopped 5
• Timing of resumption if held: If statins are discontinued, the 2006 stroke guidelines note that patients followed for up to 19 days off warfarin had no recurrent ischemic strokes, suggesting a window exists 5

Key Caveats and Pitfalls

Common mistake to avoid: Reflexively discontinuing all "blood thinners" including statins when seeing intracranial hemorrhage. Statins are NOT anticoagulants or antiplatelets—their mechanism does not directly increase bleeding risk.

The SPARCL paradox: While the SPARCL trial showed increased ICH risk with high-dose atorvastatin in stroke patients 4, this was in the context of primary prevention and very low LDL levels. The acute setting is different—discontinuing statins in patients already on them causes rebound inflammation and thrombotic risk.

Subdural vs. intracerebral hemorrhage: Most guideline evidence addresses intracerebral (parenchymal) hemorrhage. Subdural hematomas have different pathophysiology, but the principles regarding statin continuation likely apply similarly given the shared concern about discontinuation harm.

Practical Implementation

• Document the indication for statin therapy (secondary prevention after MI/stroke, diabetes, high ASCVD risk)
• If the patient has mechanical heart valve, recent coronary stent, or recent ACS, continuation is even more critical
• Avoid "statin holidays" or dose reductions without clear indication 6
• At discharge, ensure statin is continued with clear documentation in discharge summary 6

The evidence strongly favors a default position of continuation rather than discontinuation, with individualized decisions only for patients with lobar hemorrhage and no compelling cardiovascular indication, or those with contraindications to statins unrelated to the hemorrhage itself.